ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will acquire DSM's biologics manufacturing facility in Montreal for an undisclosed sum. The drug company says it will use the 66,000-sq-ft facility to manufacture antibody drug candidates for clinical trials. It plans to begin full-scale production in 2009. AstraZeneca, which is in the process of acquiring the biotech firm MedImmune and recently purchased Cambridge Antibody Technology, is on a push to expand its presence in biopharmaceuticals. DSM announced a mothballing of the Montreal plant in January 2006 as part of a restructuring of its pharmaceutical chemicals and biologics businesses.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter